Literature DB >> 17565490

Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.

Naohito Shirai1, Mitsushige Sugimoto, Chise Kodaira, Masafumi Nishino, Mutsuhiro Ikuma, Masayoshi Kajimura, Kyoichi Ohashi, Takashi Ishizaki, Akira Hishida, Takahisa Furuta.   

Abstract

BACKGROUNDS AND AIMS: Development of safe and effective rescue regimens for eradication failure of Helicobacter pylori infection by standard regimens is an urgent task. We designed the prospective study to compare the efficacy of two rescue regimens after eradication failure by the standard triple therapy.
METHODS: One hundred and thirty-two patients in whom eradication of H. pylori infection failed initial triple therapy with lansoprazole 30 mg b.i.d, amoxicillin 750 mg b.i.d. and clarithromycin 400 mg b.i.d. for 1 week were randomized to either the 1-week triple therapy with rabeprazole 10 mg b.i.d., amoxicillin 750 mg b.i.d., and metronidazole 250 mg b.i.d. (RAM) or the 2-week dual therapy with rabeprazole 10 mg q.i.d. and amoxicillin 500 mg q.i.d. (RA). Eradication of H. pylori was judged by (13)C-urea breath test 1 month later.
RESULTS: The intention-to-treat and per-protocol-based eradication rates were 92.4% (95% CI: 83.2-97.5) and 95.3% (95% CI: 86.9-99.0) for the RAM therapy and 90.9% (95% CI: 81.2-96.6) and 93.8% (95% CI: 84.8-98.3), respectively, for the RA therapy (P > 0.2 for both). No clinically recognizable adverse events were observed with either regimen.
CONCLUSION: RA as well as RAM therapy are safe and effective rescue regimens for H. pylori infection after eradication failure by the standard triple therapy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17565490     DOI: 10.1007/s00228-007-0302-8

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   3.064


  55 in total

1.  Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin.

Authors:  T Furuta; N Shirai; M Takashima; F Xiao; H Hanai; K Nakagawa; H Sugimura; K Ohashi; T Ishizaki
Journal:  Pharmacogenetics       Date:  2001-06

2.  Effect of varying pH on the susceptibility of Campylobacter pylori to antimicrobial agents.

Authors:  M L Grayson; G M Eliopoulos; M J Ferraro; R C Moellering
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-10       Impact factor: 3.267

3.  Clarithromycin-resistant Helicobacter pylori in patients with duodenal ulcer in the United States.

Authors:  N Vakil; B Hahn; D McSorley
Journal:  Am J Gastroenterol       Date:  1998-09       Impact factor: 10.864

4.  Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome.

Authors:  R J Adamek; S Suerbaum; B Pfaffenbach; W Opferkuch
Journal:  Am J Gastroenterol       Date:  1998-03       Impact factor: 10.864

5.  Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.

Authors:  Akihito Nagahara; Hiroto Miwa; Masato Kawabe; Akihiko Kurosawa; Daisuke Asaoka; Mariko Hojo; Katsuyori Iijima; Takeshi Terai; Toshifumi Ohkusa; Akihisa Miyazaki; Nobuhiro Sato
Journal:  J Gastroenterol       Date:  2004-11       Impact factor: 7.527

6.  Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.

Authors:  K Murakami; R Sato; T Okimoto; M Nasu; T Fujioka; M Kodama; J Kagawa
Journal:  Aliment Pharmacol Ther       Date:  2003-01       Impact factor: 8.171

7.  Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori.

Authors: 
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-09       Impact factor: 3.267

Review 8.  Hypotheses on the pathogenesis and natural history of Helicobacter pylori-induced inflammation.

Authors:  M J Blaser
Journal:  Gastroenterology       Date:  1992-02       Impact factor: 22.682

9.  Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin.

Authors:  J Labenz; M Stolte; A L Blum; I Jorias; F Leverkus; M Sollböhmer; J Bertrams; G Börsch
Journal:  Gut       Date:  1995-07       Impact factor: 23.059

10.  Induction of lung tumors and lymphomas in BALB/c mice by metronidazole.

Authors:  A Cavaliere; M Bacci; A Amorosi; M Del Gaudio; R Vitali
Journal:  Tumori       Date:  1983-10-31
View more
  32 in total

1.  Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan.

Authors:  Ayako Yanai; Kei Sakamoto; Masao Akanuma; Keiji Ogura; Shin Maeda
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-02-06

2.  One-day front-loading with four doses of rabeprazole followed by a standard twice-daily regimen provides sufficient acid inhibition in extensive metabolizers of CYP2C19.

Authors:  Takuma Kagami; Mitsushige Sugimoto; Hitomi Ichikawa; Shu Sahara; Takahiro Uotani; Mihoko Yamade; Yasushi Hamaya; Moriya Iwaizumi; Satoshi Osawa; Ken Sugimoto; Hiroaki Miyajima; Takahisa Furuta
Journal:  Eur J Clin Pharmacol       Date:  2015-10-02       Impact factor: 2.953

3.  Second-line rescue therapy of helicobacter pylori infection.

Authors:  Javier P Gisbert
Journal:  Therap Adv Gastroenterol       Date:  2009-11       Impact factor: 4.409

Review 4.  "Rescue" regimens after Helicobacter pylori treatment failure.

Authors:  Javier P Gisbert
Journal:  World J Gastroenterol       Date:  2008-09-21       Impact factor: 5.742

5.  ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.

Authors:  William D Chey; Grigorios I Leontiadis; Colin W Howden; Steven F Moss
Journal:  Am J Gastroenterol       Date:  2017-01-10       Impact factor: 10.864

6.  Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing: a prospective serial study.

Authors:  Yue-Xi Zhang; Li-Ya Zhou; Zhi-Qiang Song; Jian-Zhong Zhang; Li-Hua He; Yu Ding
Journal:  World J Gastroenterol       Date:  2015-03-07       Impact factor: 5.742

7.  High-dose dual therapy is effective as first-line treatment for Helicobacter pylori infection.

Authors:  Kadir Öztürk; Ömer Kurt; Gürkan Çelebi; Hakan Şarlak; Muhammed Fatih Karakaya; Hakan Demirci; Ali Kılınç; Ahmet Uygun
Journal:  Turk J Gastroenterol       Date:  2020-03       Impact factor: 1.852

8.  Effectiveness of three times daily lansoprazole/amoxicillin dual therapy for Helicobacter pylori infection in Korea.

Authors:  Seung Young Kim; Sung Woo Jung; Jeong Han Kim; Ja Seol Koo; Hyung Joon Yim; Jong Jae Park; Hoon Jai Chun; Sang Woo Lee; Jai Hyun Choi
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

9.  Changes in 12-Year First-Line Eradication Rate of Helicobacter pylori Based on Triple Therapy with Proton Pump Inhibitor, Amoxicillin and Clarithromycin.

Authors:  Makoto Sasaki; Naotaka Ogasawara; Keiko Utsumi; Naohiko Kawamura; Tskeshi Kamiya; Hiromi Kataoka; Satoshi Tanida; Tsutomu Mizoshita; Kunio Kasugai; Takashi Joh
Journal:  J Clin Biochem Nutr       Date:  2010-06-17       Impact factor: 3.114

Review 10.  New concepts of resistance in the treatment of Helicobacter pylori infections.

Authors:  David Y Graham; Akiko Shiotani
Journal:  Nat Clin Pract Gastroenterol Hepatol       Date:  2008-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.